Point72 Asset Management’s Standard BioTools LAB Stock Holding History

Point72 Asset Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.1K	Sell	44,721 -98,586	-69%	-$119K	﹤0.01%	3670
2025 Q4	$183K	Buy	+143,307	New	+$193K	﹤0.01%	3658
2024 Q2	–	Sell	-142,300	Closed	-$386K	–	2174
2024 Q1	$386K	Buy	+142,300	New	+$344K	﹤0.01%	1710
2023 Q4	–	Sell	-34,582	Closed	-$100K	–	2498
2023 Q3	$100K	Buy	+34,582	New	+$90.4K	﹤0.01%	1967
2020 Q3	–	Sell	-399,415	Closed	-$1.6M	–	1012
2020 Q2	$1.6M	Buy	+399,415	New	+$1.39M	0.01%	626
2015 Q3	–	Sell	-63,400	Closed	-$1.53M	–	844
2015 Q2	$1.53M	Buy	+63,400	New	+$2M	0.01%	590

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Point72 Asset Management's LAB Position: Q1 2026 in Review

Point72 Asset Management reduced its Standard BioTools (LAB) stake by 69% in Q1 2026, selling an estimated $119K and leaving 44,721 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3670.

Point72 Asset Management first reported a position in LAB in Q2 2015 and has held it in 6 quarters since. The position peaked at $1.6M in Q2 2020. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Point72 Asset Management held 44,721 shares of Standard BioTools worth $41.1K as of Q1 2026.
Point72 Asset Management sold 98,586 Standard BioTools shares in Q1 2026, an estimated $119K.
Standard BioTools made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3670 holding.
Point72 Asset Management first reported a position in Standard BioTools in Q2 2015 and has held it in 6 quarters since.
Point72 Asset Management's Standard BioTools position peaked at $1.6M in Q2 2020.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.